fourth ventricle. A high-signal intensity rim indicative of edema was seen in the pons adjacent to the tumor, but no obvious infiltration of the brain was detected.
Operations. A ventriculostomy was perfomed as an emergency procedure, and the extraaxial tumor (lacking an intraaxial component) involving the posterior fossa was microsurgically resected with the infant in a prone position 1 day later.
Postoperative Course. The infant was extubated and showed temporary relief of signs and symptoms. The ventricular catheter was removed, and subsequent ultrasound examination showed that the size of the ventricles remained stable. An MR imaging study performed on the 3rd postoperative day showed gross-total resection of the tumor in the posterior fossa but residual tumor at the temporal bone and clivus and more widespread edema in the brainstem (Fig. 3) . Four weeks later (36 gestational weeks) the infant's condition rapidly deteriorated, and additional MR imaging showed hydrocephalus and an even larger tumor in the posterior fossa than had been originally seen, with signal intensities and contrast enhancement pattern of the tumor identical to the original findings. The infant died the next day.
Histopathological and Autopsy Findings. Histopathological assessment of the surgical samples displayed numerous osteoclast-like giant cells surrounded by a dense population of quite homogeneous mononuclear cells that showed a high tendency toward both proliferation and apoptosis. No osteoid-like material was seen in the surgical specimen. A sarcomatous spindle cell component was detected focally but it was very limited (< 10%). Immunohistochemical staining with antibodies directed to α-fetoprotein, human gonadotrophin, placental antibody, glial fibrillary acidic protein, microtubule-associated protein 2, neurofilament, and synaptophysin were all negative. Giant cells were immunohistochemically labeled with a histiocytic marker such as CD68 but were negative for labeling with markers such as S100 protein and CD1a. Based on these findings, the tumor was classified as being a malignant GCT of the bone (Fig. 4) . At autopsy, tumor growth was seen in the posterior fossa. The cerebellum was macroscopically altered (Fig. 5a ), and in cross-sectioning of the brainstem and cerebellum some quite well demarcated nodules of tumor were seen ( Fig. 5b and c) . The histological assessment of the postmortem material revealed a GCT, consistent with previous findings in the surgical specimen (4 weeks earlier). It is noteworthy that the sarcomatous component was still inconspicuous, seen only focally. The tumor was pressing toward the brain parenchyma with a demarcated margin, and reactive gliosis was noted in the brain parenchyma itself.
Discussion
Malignancy develops in only 5-10% of GCT cases, 8, 9, 30 and most of the cases of GCTs of the cranium reported in the literature are benign. 5 Primary malignant GCTs presenting with aggressive and malignant behavior from the onset are extremely uncommon, even in the long bones of the appendicular skeleton. 24 To the best of our knowledge, only 3 cases of primary malignant GCT of the skull have been reported previously. 5, 19, 25 The first case concerned a 41-year-old man with a malignant GCT of the sphenoid bone, who received radiation therapy. No recurrence of the tumor was found 15 months after the diagnosis (last follow-up). 25 Another case of primary malignant GCT of the parietal bone was reported in an 81-year-old woman. 19 Surgical resection was performed, and histological examination of the lesion demonstrated Paget disease with a malignant GCT. The patient experienced local recurrence of the malignant GCT and eventually died 18 months after the initial presentation, having developed pulmonary metastases. Finally, the third well-documented case was a primary malignant GCT of the skull arising from the sphenoid bone in a 77-year-old man. 5 The patient and his family refused any treatment after the biopsy of the tumor, and he died 7 months later from sepsis and stroke-unrelated to the tumor, although the tumor was still present-without evidence of disseminated disease. There has been some deliberation in the literature about what constitutes a malignant GCT of the bone, 16, 24 and a variety of criteria have been used to establish the diagnosis. 21, 22 The original classification of malignant GCTs by Jaffe et al. 16 separated these lesions into 3 categories, representing a continuum from benign (Grade I) to intermediate (Grade II) and malignant (Grade III). Recent WHO recommendations 27 regarding malignancy in GCT use the terms primary and secondary malignant GCT, as originally defined by Hutter et al. 15 The secondary malignant GCT is a high-grade spindle cell sarcoma lacking residual GCT that develops at the site of a benign GCT treated surgically or with radiation therapy. 27 In the primary malignant GCT, in contrast, areas of conventional GCT are present with abrupt transition to a sarcomatous spindle cell component. 27 Histologically, in the current case the dominant feature was the clearly malignant-appearing homomorphous stroma cells intermingled with benign osteoclast-type giant cells associated with abnormal mitotic figures and combined with foci that were indistinguishable from benign GCT. In addition, conspicuous areas of the sarcomatous component were seen, and thus the diagnosis of malignant primary GCT was justified. A tumor that might be difficult to differentiate histologically from a malignant GCT, especially in patients with Paget disease, is the giant cell-rich osteosarcoma. 22 This tumor may contain fields of benign-appearing osteoclast-type giant cells, and the features of anaplasia might be minimal. For the diagnosis of giant cell-rich osteosarcoma in the midst of the neoplastic cells, osteoid (that is, tumor bone produced by the atypical stromal cells) is seen.
Radiographic features of GCTs typically include a radiolucent, osteolytic lesion causing bone erosion, 7 with- out a sclerotic rim, but with sharp margins on CT.
14 The plain film characteristics of GCTs in adults are indistinguishable from those of other radiolucent lesions of the skull. Magnetic resonance imaging demonstrates a wellcircumscribed lesion that is isointense on T1-weighted images and hypointense on both T2-weighted and diffusion-weighted images. The mass typically enhances heterogeneously. The major radiological differential diagnosis includes giant cell reparative granuloma and brown tumors of hyperparathyroidism. 6, 28 A CT study alone is not sufficient for the differentiation of GCTs from these lesions. However, giant cell granulomas are often preceded by a history of tooth extraction or trauma, while brown tumors are usually multiple and demonstrate other imaging and laboratory evidence of hyperparathyroidism. The MR imaging characteristics of the tumor in our neonatal case showed a characteristically hypointense pattern on T2-weighted images, but the other characteristics were less typical; on the T1-weighted images the signal was hyperintense, and the enhancement pattern was homogeneous rather than heterogeneous as reported previously. Although the tumor origin from the bone was correctly depicted, and the aggressive malignant behavior was obvious on the basis of the previous normal ultrasound examinations, the accurate histopathological diagnosis could not be predicted from the MR images.
The definitive treatment for GCTs of the bone is surgical extirpation. The value of radiation therapy is debated because GCTs were initially thought to be radioresistant and malignant transformation following radiation treatment has occurred. 20 However, advances in radiation therapy have led to recent reports of its safety and efficacy in the management of GCTs, 18, 32 especially when either the lesions are anatomically inaccessible or surgical excision is judged to be incomplete. 2 In addition, chemotherapy using adriamycin has proved to be effective in controlling local disease in surgically inaccessible and radioresistant tumors, as well as in remnant or recurrent tumors. 33 As diagnosed in our patient, primary malignant GCTs are extremely rare. 3, 29, 31 The prognosis for a patient with such a tumor is poor, and most of the patients die rapidly, usually within a few months to 1 year. 9, 13, 15 To the best of our knowledge, we present the most aggressive GCT of the skull ever reported, since our patient died 1 month after surgery with a tumor larger than it was before the operation. Because of the rarity of malignant GCTs of the skull, no consensus on treatment or prognosis can be proposed. However, complete surgical excision to forestall local recurrence should be the goal, with radiation therapy and/or chemotherapy reserved for unresectable or incompletely extirpated tumors. Unfortunately, in the case we present here, the progress of the tumor in the postoperative period was so extremely rapid that there was no time for additional interventions.
Conclusions
Primary malignant GCTs of the skull are extremely rare and only 3 cases have been reported to date, all of which were in patients over the age of 40 years. This report contributes another case of a primary malignant GCT of the skull to the literature. It is noteworthy that the case described here was highly malignant, being the most aggressive malignant GCT of the skull ever reported. Histologically the tumor displayed a conspicuous sarcomatous component whereas the conventional GCT pattern with brisk mitotic activity dominated. More importantly, our case represents the youngest patient harboring such a tumor. The rapid progression to death due to recurrence of the tumor just 1 month after surgery was quite unexpected.
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